Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-851-2 | CAS number: 88-68-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Information from public copy of a correspondance letter to US EPA, reliability not known but contributing to a weight of evidence assessment.
Data source
Reference
- Reference Type:
- other: Public copy of a correspondance letter to US EPA
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- A 2-year feeding study is being conducted in Crl:CD(SD) rats (SO/sex/concentration) with the test substance at dietary concentrations of 0, 20, 200, 2000, or 20000 ppm. This notification covers effects through the one-year interim sacrifice. The rats have been observed for mortality, clinical signs, body weight effects, and food consumption, and rats received an ophthalmologic examination after ~ 1 year of dosing. Ten rats/sex/concentration were designated for evaluation of chronic toxicity. These rats were evaluated for clinical pathology at ~6 and 12 months and for anatomic pathology (organ weights, gross and microscopic pathology) at the end of 12 months.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Anthranilamide
- EC Number:
- 201-851-2
- EC Name:
- Anthranilamide
- Cas Number:
- 88-68-6
- Molecular formula:
- C7H8N2O
- IUPAC Name:
- 2-aminobenzamide
- Test material form:
- solid: crystalline
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- not specified
- Duration of treatment / exposure:
- 12 months
Doses / concentrationsopen allclose all
- Dose / conc.:
- 20 ppm
- Dose / conc.:
- 200 ppm
- Dose / conc.:
- 2 000 ppm
- Dose / conc.:
- 20 000 ppm
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
Examinations
- Observations and examinations performed and frequency:
- The rats have been observed for mortality, clinical signs, body weight effects, and food consumption, and rats received an ophthalmologic examination after ~ 1 year of dosing.
- Sacrifice and pathology:
- These rats were evaluated for clinical pathology at 6 and 12 months and for anatomic pathology (organ weights, gross and microscopic pathology) at the end of 12 months.
Results and discussion
Results of examinations
- Details on results:
- Mild reductions in mean body weight, body weight gain, food consumption, and food efficiency were observed in females in the 2000 ppm and 20000 ppm groups compared to control. Mild reductions in food efficiency were observed in the male 2000 ppm and 20000 ppm groups. Clinical observations included subdued behavior, ataxic gait, dragging hindlimbs, and tilted head.These were only observed in isolated cases involving 1 animal in any dose group throughthe one year time point, and did not exhibit a dose-response. The following clinical chemistry changes were observed in males (not all statistically significant or clear dose response and many differences of small magnitude) at 6 and/or 12 months: at 20000 ppm - HGB, MCRC, AST, bilirubin, ALKP, i Ca; at 2000 ppm - ! bilirubin, i hemoglobin distribution width, Ca, cholesterol, triglycerides, Na; At 200 ppm - ! RBC ghosts, i HGB, Na; and at 20 ppm - ! BUN.
The following clinical chemistry changes were observed in females (not all statistically significant) at 6 and/or 12 months: at 20000 ppm - ! prothrombin time (PT), triglycerides, AST,ALT, bilirubin, Cl, i red cell distribution width, cholesterol, Ca: at 2000 ppm - ! HGB, MCHC, RBC ghosts, prothrombin time (PT), AST, bilirubin, ired cell distribution width, activated partial thromboplastin time (APTT), cholesterol, Ca, total protein, globulin, CI; at 200 ppm - ! RBC ghosts, AST; and at 20 ppm i total protein, globulin. None of these differences was considered to be adverse or test substance related except the increased cholesterol in females at 2000 or 20000 ppm. No gross observations at necropsy were attributed to test substance exposure. Test substance-related increases in absolute and/or relative liver weights were observed in males and females at 2000 and 20000 ppm. Non-statistically significant elevations in liver weights were also observed in 20 and 200 ppm female groups. Correlative centrilobular hepatocellular hypertrophy (minimal or mild) was observed in 20000 ppm males and females and in 200 and 2000 ppm females. Minimal or mild vacuolar degeneration of the liver was also observed in 2000 and 20000 ppm males; however, no correlative clinical pathology effects were observed. Other statistically significant organ weight changes were increased relative kidney weight (2000 and 20000 ppm females), increased absoluteheart weight (2000 ppm males), and increased relative heart weigh (2000 ppm females). No microscopic pathology correlates were observed. Other microscopic pathology lesions attributed to test substance exposure were increased adrenal cortical microvesiculation (minimal) in 20000 ppm females and increased thyroid gland follicular cell hypertrophy (minimal) in 2000 and 20000 ppm females. Uterine squamous metaplasia (minimal) was observed in all dose groups, but not in controls. However, the incidence was highest in the 20 ppm group and did not display a doseresponse; therefore, the detennination of whether or not this lesion is test substance related will be made based on overall incidence at the end of the study.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.